Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$75.77 USD

75.77
869,339

-0.34 (-0.45%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $75.81 +0.04 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zimmer Biomet Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.

Zacks Equity Research

Neogen (NEOG) Q2 Earnings & Revenues Miss, Margin Rises

by Zacks Equity Research

Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.

Zacks Equity Research

GNC Holdings Launches Energy Drink With Natural Extracts

by Zacks Equity Research

GNC Holdings (GNC) launches natural ingredient-based energy drink MAD PONY ENERGY.

Zacks Equity Research

NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance

by Zacks Equity Research

Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.

Zacks Equity Research

Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes

by Zacks Equity Research

Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.

Zacks Equity Research

Here's Why You Should Hold on to Globus Medical Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) on its stellar segmental performance.

Zacks Equity Research

Medtronic's (MDT) Brain Therapies Device Receives FDA Approval

by Zacks Equity Research

Medtronic (MDT) strengthens its robotics platform with the receipt of regulatory approval and the subsequent upgradation of its enabling technology portfolio.

Zacks Equity Research

Medtronic Acquires Klue to Strengthen Diabetes Management Arm

by Zacks Equity Research

Medtronic (MDT) strengthens its diabetes business through the Klue acquisition and subsequent development of its PCL technology.

Zacks Equity Research

Here's Why You Should Retain Integra LifeSciences Stock Now

by Zacks Equity Research

Investors can hold on to Integra LifeSciences (IART) stock in their portfolio owing to solid prospects.

Zacks Equity Research

Insulet Rides on Innovation, Omnipod's Wider Market Appeal

by Zacks Equity Research

The full-market commercial launch of Insulet's (PODD) Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System is encouraging.

Zacks Equity Research

Medtronic (MDT) Inks Deal to Focus on Value-Based Healthcare

by Zacks Equity Research

With shared financial responsibility between ChristianaCare and Medtronic (MDT), this coordinated effort will improve patient outcomes at reduced cost.

Zacks Equity Research

Myriad Genetics Presents Trial Outcomes in Breast Health

by Zacks Equity Research

Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.

Zacks Equity Research

ResMed (RMD) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

ResMed (RMD) gains from impressive performance of its SaaS business.

Zacks Equity Research

Cardiovascular Systems Sees Peripheral OAS Micro Crown Success

by Zacks Equity Research

This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.

Zacks Equity Research

Globus Medical Rides on New Product Menu, U.S. Spine Business

by Zacks Equity Research

Globus Medical's (GMED) U.S. Spine business is securing a market share on the back of competitive representative recruiting and an implant pull-through from ExcelsiusGPS installations.

Zacks Equity Research

Tandem Diabetes Gets FDA Nod for t:slim X2 Insulin Pump

by Zacks Equity Research

The FDA nod for Tandem Diabetes' (TNDM) t:slim X2 insulin pump with Control-IQ will speed up its pump shipments within the United States and grow its clientele.

Zacks Equity Research

Boston Scientific Hits New 52-Week High: What's Driving it?

by Zacks Equity Research

Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.

Zacks Equity Research

Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod

by Zacks Equity Research

Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.

Zacks Equity Research

Neogen's Food Safety Business Thrives on Ergot Alkaloids Test

by Zacks Equity Research

The newly-developed Reveal Q+ MAX test is likely to fortify Neogen's (NEOG) presence in the global food allergen testing market.

Zacks Equity Research

Bruker Launches Luxendo TruLive3D Imager, Expands NANO Arm (Revised)

by Zacks Equity Research

Bruker's (BRKR) latest Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environments.

Zacks Equity Research

Intersect ENT (XENT) Grows on Innovation Despite Cost Woes

by Zacks Equity Research

The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.

Zacks Equity Research

Walgreens Extends Deal to Form GPO With Retail Giant Kroger

by Zacks Equity Research

Per Walgreens (WBA), its alliance with Kroger will lead to supply chain efficiencies, capitalizing on their joint resources.

Zacks Equity Research

Here's Why You Should Hold on to Quest Diagnostics Stock Now

by Zacks Equity Research

Investors can retain Quest Diagnostics (DGX) stock in their portfolio, thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Add Omnicell to Your Portfolio Now

by Zacks Equity Research

Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.